Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies.

Jerome Fayette, Claire Cropet, Julien Gautier, Clemence Toullec, Mickael Burgy, Amandine Bruyas, Christian Sire, Aurelie Lagrange, Florian Clatot, Benoit Calderon, Marie Vinches, Mariana Iacob, Laurent Martin, Eve Marie Neidhardt Berard, Marie-Christine Kaminsky, Damien Vansteene, Sébastien Salas

J Clin Oncol 41, June 2023 (suppl; abstr 6003)

A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck (R/M SCCHN): Interim analysis on 199 patients—The TOPNIVO study on behalf of the GORTEC and the Unicancer Head & Neck Group.

Caroline Even, Amaury Daste, Esma Saada-Bouzid, Gautier Lefebvre, Jerome Fayette, Sylvie Zanetta, Marie-Christine Kaminsky, Didier Cupissol, Alain Prevost, Elodie Vauleon, Alison Claire Johnson, Sebastien Salas, Frederic Rolland, Miruna Timar David, Isabelle Jallut, Jessy Delaye, Jean Bourhis, Joel Guigay, Matthieu Texier, Anne Auperin

J Clin Oncol 37, 2019 (suppl; abstr 6032)

TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

Joel Guigay, Jerome Fayette, Ricard Mesia, Cedrik Lafond, Esma Saada-Bouzid, Lionnel Geoffrois, Laurent Martin, Didier Cupissol, Olivier Capitain, Helene Castanie, Damien Vansteene, Philippe Schafhausen, Catherine Dubos Arvis, Caroline Even, Christian Sire, Melissa Delhommeau, Cecile Michel, Jean Bourhis, Ulrich Keilholz, Anne Auperin

J Clin Oncol 37, 2019 (suppl; abstr 6002)

Hyperfractionated reirradiation with cetuximab for recurrent head and neck cancer: The GORTEC 2008-01 multicentric phase II study.

Mathilde Saint-Ghislain, Yungan Tao, Marc Alfonsi, Pierre Boisselier, Muriel Garcia-Ramirez, Claude Tuchais, Philippe Maingon, Christian Sire, Ali Hasbini, Marie Saliou, Cedrik Lafond, Hao Qiu, Sébastien Guihard, Pascal Garaud, marie-Helene Calais, Juliette Thariat, Laurent Martin, Jean Bourhis

J Clin Oncol 36, 2018 (suppl; abstr 6034)

Avelumab-cetuximab-radiotherapy (RT) versus standards of care (SoC) in locally advanced squamous cell carcinoma of the head and neck (SCCHN): Safety phase of the randomized trial GORTEC 2017-01 (REACH).

Yungan Tao, Anne Auperin, Xu Shan Sun, Christian Sire, Laurent Martin, G Bera, Alexandre Coutte, Jessica Miroir, Cedrik Lafond, Natacha Colin-Batailhou, Aline Maillard, Laurent Gibel, Cécile Michel, Joel Guigay, Jean Bourhis

J Clin Oncol 36, 2018 (suppl; abstr 6076)

A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 “PembroRad” trial.

Xu Shan Sun, Christian Sire, Yungan Tao, Laurent Martin, Marc Alfonsi, Jean Briac Prevost, Michel Rives, Cedrik Lafond, Jean-Marc Tourani, Julian Biau, Lionnel Geoffrois, Alexandre Coutte, Xavier Liem, Elodie Vauleon, Franck Drouet, Jean-François Ramee, Gabriel Waksi, Laura Sinigaglia, Anne Auperin, Jean Bourhis

J Clin Oncol 36, 2018 (suppl; abstr 6018)

853O OMITting frontline chemotherapy in head and neck cancer (HNSCC) patients with 1-3 oligometastases using stereotactic ablative radiotherapy (SABR), the GORTEC 2014-04 “OMET” randomized phase II trial

J. Thariat, M. Bosset, A. Falcoz, D. Vernerey, Y. Pointreau, S. Racadot, J.C. Faivre, J. Castelli, S. Guihard, F. Huguet, S. Chapet, Y. Tao, J. Bourhis, X.S. Sun,

Annals of Oncology oct 2023, Abstract 8530,Volume 34 suppl 2, S554

Double-blind Randomized Phase 2 Results Comparing Concurrent High-dose Cisplatin Chemorradiation (CRT) plus Debio 1143 or Placebo In High-risk Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN): A GORTEC Study

J. Bourhis, X. Sun, Y. Pointreau, C. Sire, C. Le Tourneau, A. Coutte, M. Kaminsky-Forrett, M. Alfonsi, P. Boisselier, L. Martin, J. Delord, F. Clatot, J. Miroir, F. Rolland, P. Crompton, S. Brienza, S.A. Szyldergemajn, C. Even, Y. Tao

Annals of Oncology (2019) 30 (suppl_5): v851-v934. 10.1093/annonc/mdz394

Double-blind Randomized Phase 2 Results Comparing Concurrent High-dose Cisplatin Chemorradiation (CRT) plus Debio 1143 or Placebo In High-risk Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN): A GORTEC Study by Jean Bourhis

ELAN FIT ELAN UNFIT

Barcelona 2019 ESMO Congress - Oral Presentation

Personalized treatment according to geriatric assessment in 1st line recurrent and/or metastatic (r/m) Head and Neck Squamous Cell Cancer (HNSCC) patients aged 70 or over.
Publication PDF

J. Guigay, A. Auperin, C. Mertens, C. Even, L. Geoffrois, D. Cupissol, F. Rolland, C. Sire, J. Fayette, F. Peyrade, E. Blot, P. Debourdeau, L. Bozec Le Moal, O. Capitain, Y. Pointreau, C. Brard, C. Michel, D. Schwob, C. Ortholan, H. Le Caer

Concurrent cisplatin and Dose escalation with Intensity-modulated radiotherapy (IMRT) versus conventional chemo-radiotherapy for locally advanced (LA) head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial

Y. Tao, A. Auperin, P. Blanchard, M. Alfonsi, X. Sun, M. Rives, Y. Pointreau, J. Castelli, P. Graff, S. Wong Hee Kam, J. Thariat, O. Veresezan, A. Cornely, O. Casiraghi, M. Lapeyre, J. Bourhis

Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287

TOPNIVO - A safety study of Nivolumab in Patients with Recurrent and/or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN): first results on behalf of the Unicancer Head&Neck Group and the GORTEC.

C. Even, A. Daste, E. Saada-Bouzid, J. Fayette, M. Kaminsky-Forrett, S. Zanetta, A. Prevost, G. Lefebvre, C. Borel, D. Cupissol, F. Huguet, J. Delord, N. Baste Rotllan, J. Delaye, I. Jallut, N. Vintonenko, J. Bourhis, J. Guigay, M. Texier, A. Auperin

Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287

1108TiP - Chemoradiotherapy versus radiotherapy in the treatment of salivary glands and nasal tumors: the GORTEC 2016-02 study

F.R. Ferrand, J. Thariat, N. Vulquin, V. Calugaru, O. Malard, C. Murariu, F. Janot, F. Louat, C. Michel, J. Bourhis

Annals of Oncology (2017) 28 (suppl_5): v372-v394. 10.1093/annonc/mdx374

Hope for salivary gland cancer (SGC): EORTC HNCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of Chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptor (AR) expressing SGC

L.D. Locati, C. Caballero, C. Fortpied, F. Perrone, S. Pilotti, K.J. Harrington, V. Grégoire, L. Licitra

Annals of Oncology (2017) 28 (suppl_5): v372-v394. 10.1093/annonc/mdx374

Dose escalation of radiotherapy (RT) for locally advanced head and neck carcinomas treated with concomitant chemotherapy (CT) and RT: Results of the GORTEC 2004-01 randomized trial.

Jean Bourhis, Anne Auperin, Marc Alfonsi, xu Shan Sun, Michel Rives, Yoann Pointreau, Cedrik Lafond, Pierre Boisselier, Pierre Graff, Juliette Thariat, Yungan Tao

J Clin Oncol 35, 2017 (suppl; abstr 6015)

Impact of p16 expression on induction taxotere-cisplatin-5 FU (TPF) followed by cetuximab-radiotherapy in N2b-N3 head and neck squamous cell carcinoma (HNSCC): Results of GORTEC 2007-02 phase III randomized trial.

Yungan Tao, Lionnel Geoffrois, Laurent Martin, Dominique De Raucourt, Joelle Miny, Philippe Maingon, Cedrik Lafond, Claude Tuchais, Christian Sire, Emmanuel Babin, Alexandre Coutte, Frederic Rolland, Marie-Helene Girard-Calais, Odile Casiraghi, Pascal Garaud, Jean Bourhis

J Clin Oncol 35, 2017 (suppl; abstr 6070)

OC-0332: Impact of HPV on effect of chemotherapy in SCCHN : results of the GORTEC 2007-01 randomized trial

X. Sun, Y. Tao, A. Auperin, C. Sire, L. Martin, C. Khoury, P. Maingon, E. Bardet, and others

Radiotherapy and Oncology, Vol. 123, S175
Published in issue: May 2017